Disitamab Vedotin (RC48-ADC) in Breast Cancer
Study Details
Design, interventions, and primary outcomes
About This Study
To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients with breast cancer.
Design
Interventions / Regimen
- Drug: Disitamab vedotin — recommended but not required regimen of 2.0mg/kg, iv, day1, every 2 weeks
Primary Outcomes
- Progression-Free Survival (From the date of starting Disitamab vedotin to the date of first documentation of progression or death (up to approximately 1 years))
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-06-01
Completion: 2027-08
Sex: ALL
Volunteers: false
Enrollment: 45 (ESTIMATED)
- Wenjin Yin, M.D. (PRINCIPAL_INVESTIGATOR) - Renji Hospital,School of Medicine, Shanghai Jiaotong University
- Drug: Disitamab vedotin — recommended but not required regimen of 2.0mg/kg, iv, day1, every 2 weeks